H. Maeda

Biomaterials · Advanced Drug Delivery Reviews · 2000–2020

A researcher in the Science corpus: 11 papers; trusts 4 researchers and is trusted by 54 researchers here, as inferred from the citation graph.

Subfields

• Biomaterials — 32 citations into it; #117 of 2,152 by trust here, #288 by citations
• Biomedical Engineering — 20 citations into it; #423 of 10,734 by trust here, #1,372 by citations
• Materials Chemistry — 12 citations into it; #3,792 of 11,513 by trust here, #4,577 by citations
• Cancer Research — 6 citations into it; #1,385 of 1,780 by trust here, #545 by citations

Whom H. Maeda trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Rakesh K. Jain
2. Jun Fang
3. Hideaki Nakamura
4. Joseph W. Nichols

Who trusts H. Maeda overall

1. Jun Wu
2. Hisataka Kobayashi
3. Vladimir Torchilin
4. Basit Yameen
5. Jun Fang
6. O. Farokhzad
7. K. Greish
8. M. Ernsting
9. N. Bertrand
10. R. Watanabe

Papers from H. Maeda's perspective

Ordered by how strongly the researchers H. Maeda trusts endorse each paper. Same corpus, a different order for every researcher.

1. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. (Journal of Clinical Oncology)
2. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile (Science Translational Medicine)
3. Delivering nanomedicine to solid tumors (Nature Reviews Clinical Oncology)
4. Pathology: Cancer cells compress intratumour vessels (Nature)
5. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy (Nature Medicine)
6. Openings between defective endothelial cells explain tumor vessel leakiness. (American Journal of Pathology)
7. The effect of particle design on cellular internalization pathways (Proceedings of the National Academy of Sciences of the United States of America)
8. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors (Proceedings of the National Academy of Sciences of the United States of America)
9. Role of extracellular matrix assembly in interstitial transport in solid tumors. (Cancer Research)
10. Dissecting tumour pathophysiology using intravital microscopy (Nature Reviews. Cancer)

Their papers

• The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. (2001) — 2,337 citations
• The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. (2011) — 3,316 citations
• Challenges and key considerations of the enhanced permeability and retention (EPR) effect for nanomedicine drug delivery in oncology (2013) — 1,264 citations
• Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. (2010) — 979 citations
• The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. (2013) — 2,165 citations
• Genome sequencing and analysis of Aspergillus oryzae (2005) — 1,234 citations
• Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. (2015) — 1,059 citations
• Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. (2020) — 601 citations
• Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. (2012) — 763 citations
• Exploiting the enhanced permeability and retention effect for tumor targeting. (2006) — 1,770 citations
• Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. (2000) — 6,027 citations